KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Non Operating Income (2018 - 2025)

Moderna (MRNA) has disclosed Non Operating Income for 8 consecutive years, with -$12.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 58.62% to -$12.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.0 million through Dec 2025, up 90.8% year-over-year, with the annual reading at -$8.0 million for FY2025, 90.8% up from the prior year.
  • Non Operating Income for Q4 2025 was -$12.0 million at Moderna, down from $8.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $14.0 million in Q2 2023, with the low at -$51.0 million in Q3 2023.
  • Average Non Operating Income over 5 years is -$15.4 million, with a median of -$12.0 million recorded in 2022.
  • The sharpest move saw Non Operating Income crashed 900.0% in 2021, then skyrocketed 207.69% in 2023.
  • Over 5 years, Non Operating Income stood at -$7.0 million in 2021, then plummeted by 71.43% to -$12.0 million in 2022, then crashed by 225.0% to -$39.0 million in 2023, then rose by 25.64% to -$29.0 million in 2024, then surged by 58.62% to -$12.0 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$12.0 million, $8.0 million, and -$4.0 million for Q4 2025, Q2 2025, and Q1 2025 respectively.